世界の腫瘍壊死因子（TNF）阻害薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-6054 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、96ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、腫瘍壊死因子（TNF）阻害薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（Humira、Enbrel、Remicade、Simponi/Simponi Aria、Cimzia、バイオシミラー）、用途別市場規模（関節リウマチ、乾癬、乾癬性関節炎、クローン病、潰瘍性大腸炎、強直性脊椎炎、若年性特発性関節炎、化膿性汗腺炎、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・腫瘍壊死因子（TNF）阻害薬の市場動向 ・企業の競争状況、市場シェア ・腫瘍壊死因子（TNF）阻害薬の種類別市場規模と予測2016-2027（Humira、Enbrel、Remicade、Simponi/Simponi Aria、Cimzia、バイオシミラー） ・腫瘍壊死因子（TNF）阻害薬の用途別市場規模と予測2016-2027（関節リウマチ、乾癬、乾癬性関節炎、クローン病、潰瘍性大腸炎、強直性脊椎炎、若年性特発性関節炎、化膿性汗腺炎、その他） ・腫瘍壊死因子（TNF）阻害薬の北米市場規模2016-2027（アメリカ、カナダ） ・腫瘍壊死因子（TNF）阻害薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・腫瘍壊死因子（TNF）阻害薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・腫瘍壊死因子（TNF）阻害薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・腫瘍壊死因子（TNF）阻害薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（AbbVie Inc.、Amgen Inc.、Johnson & Johnson Services, Inc.、UCB S.A.、Novartis International AG、Pfizer, Inc.、Merck & co., Inc.） ・結論

A TNF inhibitor is a pharmaceutical drug that suppresses the physiologic response to tumor necrosis factor (TNF), which is part of the inflammatory response. TNF is involved in autoimmune and immune-mediated disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriasis, hidradenitis suppurativa and refractory asthma, so TNF inhibitors may be used in their treatment. The important side effects of TNF inhibitors include lymphomas, infections (especially reactivation of latent tuberculosis), congestive heart failure, demyelinating disease, a lupus-like syndrome, induction of auto-antibodies, injection site reactions, and systemic side effects.
The market growth is expected to be driven by new product launches, promising pipeline, increasing incidence of autoimmune diseases, and a significant rise in consumer awareness regarding Tumor Necrosis Factor (TNF).

Market Analysis and Insights: Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market
The global Tumor Necrosis Factor (TNF) Inhibitor Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Tumor Necrosis Factor (TNF) Inhibitor Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Tumor Necrosis Factor (TNF) Inhibitor Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Tumor Necrosis Factor (TNF) Inhibitor Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Tumor Necrosis Factor (TNF) Inhibitor Drugs market.

Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Scope and Market Size
Tumor Necrosis Factor (TNF) Inhibitor Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Tumor Necrosis Factor (TNF) Inhibitor Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Humira
Enbrel
Remicade
Simponi/Simponi Aria
Cimzia
Biosimilars

Segment by Application
Rheumatoid Arthritis
Psoriasis
Psoriatic Arthritis
Crohn’s Disease
Ulcerative Colitis
Ankylosing Spondylitis
Juvenile Idiopathic Arthritis
Hidradenitis Suppurativa
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
AbbVie Inc.
Amgen Inc.
Johnson & Johnson Services, Inc.
UCB S.A.
Novartis International AG
Pfizer, Inc.
Merck & co., Inc.

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Humira
1.2.3 Enbrel
1.2.4 Remicade
1.2.5 Simponi/Simponi Aria
1.2.6 Cimzia
1.2.7 Biosimilars
1.3 Market by Application
1.3.1 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Rheumatoid Arthritis
1.3.3 Psoriasis
1.3.4 Psoriatic Arthritis
1.3.5 Crohn’s Disease
1.3.6 Ulcerative Colitis
1.3.7 Ankylosing Spondylitis
1.3.8 Juvenile Idiopathic Arthritis
1.3.9 Hidradenitis Suppurativa
1.3.10 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Perspective (2016-2027)
2.2 Tumor Necrosis Factor (TNF) Inhibitor Drugs Growth Trends by Regions
2.2.1 Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Tumor Necrosis Factor (TNF) Inhibitor Drugs Historic Market Share by Regions (2016-2021)
2.2.3 Tumor Necrosis Factor (TNF) Inhibitor Drugs Forecasted Market Size by Regions (2022-2027)
2.3 Tumor Necrosis Factor (TNF) Inhibitor Drugs Industry Dynamic
2.3.1 Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Trends
2.3.2 Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Drivers
2.3.3 Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Challenges
2.3.4 Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Tumor Necrosis Factor (TNF) Inhibitor Drugs Players by Revenue
3.1.1 Global Top Tumor Necrosis Factor (TNF) Inhibitor Drugs Players by Revenue (2016-2021)
3.1.2 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share by Players (2016-2021)
3.2 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue
3.4 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Concentration Ratio
3.4.1 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue in 2020
3.5 Tumor Necrosis Factor (TNF) Inhibitor Drugs Key Players Head office and Area Served
3.6 Key Players Tumor Necrosis Factor (TNF) Inhibitor Drugs Product Solution and Service
3.7 Date of Enter into Tumor Necrosis Factor (TNF) Inhibitor Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Tumor Necrosis Factor (TNF) Inhibitor Drugs Breakdown Data by Type
4.1 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Historic Market Size by Type (2016-2021)
4.2 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Forecasted Market Size by Type (2022-2027)

5 Tumor Necrosis Factor (TNF) Inhibitor Drugs Breakdown Data by Application
5.1 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Historic Market Size by Application (2016-2021)
5.2 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size (2016-2027)
6.2 North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Type
6.2.1 North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Type (2016-2021)
6.2.2 North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Type (2022-2027)
6.2.3 North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Type (2016-2027)
6.3 North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Application
6.3.1 North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Application (2016-2021)
6.3.2 North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Application (2022-2027)
6.3.3 North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Application (2016-2027)
6.4 North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country
6.4.1 North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country (2016-2021)
6.4.2 North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size (2016-2027)
7.2 Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Type
7.2.1 Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Type (2016-2021)
7.2.2 Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Type (2022-2027)
7.2.3 Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Type (2016-2027)
7.3 Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Application
7.3.1 Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Application (2016-2021)
7.3.2 Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Application (2022-2027)
7.3.3 Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Application (2016-2027)
7.4 Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country
7.4.1 Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country (2016-2021)
7.4.2 Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size (2016-2027)
8.2 Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Type
8.2.1 Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Application
8.3.1 Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Application (2016-2027)
8.4 Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Region
8.4.1 Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size (2016-2027)
9.2 Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Type
9.2.1 Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Type (2016-2021)
9.2.2 Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Type (2022-2027)
9.2.3 Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Type (2016-2027)
9.3 Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Application
9.3.1 Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Application (2016-2021)
9.3.2 Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Application (2022-2027)
9.3.3 Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Application (2016-2027)
9.4 Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country
9.4.1 Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country (2016-2021)
9.4.2 Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size (2016-2027)
10.2 Middle East & Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Type
10.2.1 Middle East & Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Application
10.3.1 Middle East & Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Application (2016-2027)
10.4 Middle East & Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country
10.4.1 Middle East & Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 AbbVie Inc.
11.1.1 AbbVie Inc. Company Details
11.1.2 AbbVie Inc. Business Overview
11.1.3 AbbVie Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Introduction
11.1.4 AbbVie Inc. Revenue in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2016-2021)
11.1.5 AbbVie Inc. Recent Development
11.2 Amgen Inc.
11.2.1 Amgen Inc. Company Details
11.2.2 Amgen Inc. Business Overview
11.2.3 Amgen Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Introduction
11.2.4 Amgen Inc. Revenue in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2016-2021)
11.2.5 Amgen Inc. Recent Development
11.3 Johnson & Johnson Services, Inc.
11.3.1 Johnson & Johnson Services, Inc. Company Details
11.3.2 Johnson & Johnson Services, Inc. Business Overview
11.3.3 Johnson & Johnson Services, Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Introduction
11.3.4 Johnson & Johnson Services, Inc. Revenue in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2016-2021)
11.3.5 Johnson & Johnson Services, Inc. Recent Development
11.4 UCB S.A.
11.4.1 UCB S.A. Company Details
11.4.2 UCB S.A. Business Overview
11.4.3 UCB S.A. Tumor Necrosis Factor (TNF) Inhibitor Drugs Introduction
11.4.4 UCB S.A. Revenue in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2016-2021)
11.4.5 UCB S.A. Recent Development
11.5 Novartis International AG
11.5.1 Novartis International AG Company Details
11.5.2 Novartis International AG Business Overview
11.5.3 Novartis International AG Tumor Necrosis Factor (TNF) Inhibitor Drugs Introduction
11.5.4 Novartis International AG Revenue in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2016-2021)
11.5.5 Novartis International AG Recent Development
11.6 Pfizer, Inc.
11.6.1 Pfizer, Inc. Company Details
11.6.2 Pfizer, Inc. Business Overview
11.6.3 Pfizer, Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Introduction
11.6.4 Pfizer, Inc. Revenue in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2016-2021)
11.6.5 Pfizer, Inc. Recent Development
11.7 Merck & co., Inc.
11.7.1 Merck & co., Inc. Company Details
11.7.2 Merck & co., Inc. Business Overview
11.7.3 Merck & co., Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Introduction
11.7.4 Merck & co., Inc. Revenue in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2016-2021)
11.7.5 Merck & co., Inc. Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Humira
Table 3. Key Players of Enbrel
Table 4. Key Players of Remicade
Table 5. Key Players of Simponi/Simponi Aria
Table 6. Key Players of Cimzia
Table 7. Key Players of Biosimilars
Table 8. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 10. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Regions (2016-2021) & (US$ Million)
Table 11. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Regions (2016-2021)
Table 12. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 13. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Regions (2022-2027)
Table 14. Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Trends
Table 15. Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Drivers
Table 16. Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Challenges
Table 17. Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Restraints
Table 18. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Players (2016-2021) & (US$ Million)
Table 19. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Players (2016-2021)
Table 20. Global Top Tumor Necrosis Factor (TNF) Inhibitor Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Tumor Necrosis Factor (TNF) Inhibitor Drugs as of 2020)
Table 21. Ranking of Global Top Tumor Necrosis Factor (TNF) Inhibitor Drugs Companies by Revenue (US$ Million) in 2020
Table 22. Global 5 Largest Players Market Share by Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue (CR5 and HHI) & (2016-2021)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Tumor Necrosis Factor (TNF) Inhibitor Drugs Product Solution and Service
Table 25. Date of Enter into Tumor Necrosis Factor (TNF) Inhibitor Drugs Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Type (2016-2021) (US$ Million)
Table 28. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share by Type (2016-2021)
Table 29. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 30. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 31. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size Share by Application (2016-2021) & (US$ Million)
Table 32. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share by Application (2016-2021)
Table 33. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 34. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 35. North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Type (2016-2021) (US$ Million)
Table 36. North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 37. North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Application (2016-2021) (US$ Million)
Table 38. North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 39. North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 40. North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 41. Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Type (2016-2021) (US$ Million)
Table 42. Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 43. Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Application (2016-2021) (US$ Million)
Table 44. Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 45. Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 46. Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Type (2016-2021) (US$ Million)
Table 48. Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Application (2016-2021) (US$ Million)
Table 50. Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 51. Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Region (2016-2021) & (US$ Million)
Table 52. Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Region (2022-2027) & (US$ Million)
Table 53. Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Type (2016-2021) (US$ Million)
Table 54. Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 55. Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Application (2016-2021) (US$ Million)
Table 56. Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 57. Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 58. Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Type (2016-2021) (US$ Million)
Table 60. Middle East & Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Application (2016-2021) (US$ Million)
Table 62. Middle East & Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 63. Middle East & Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 64. Middle East & Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 65. AbbVie Inc. Company Details
Table 66. AbbVie Inc. Business Overview
Table 67. AbbVie Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Product
Table 68. AbbVie Inc. Revenue in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2016-2021) & (US$ Million)
Table 69. AbbVie Inc. Recent Development
Table 70. Amgen Inc. Company Details
Table 71. Amgen Inc. Business Overview
Table 72. Amgen Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Product
Table 73. Amgen Inc. Revenue in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2016-2021) & (US$ Million)
Table 74. Amgen Inc. Recent Development
Table 75. Johnson & Johnson Services, Inc. Company Details
Table 76. Johnson & Johnson Services, Inc. Business Overview
Table 77. Johnson & Johnson Services, Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Product
Table 78. Johnson & Johnson Services, Inc. Revenue in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2016-2021) & (US$ Million)
Table 79. Johnson & Johnson Services, Inc. Recent Development
Table 80. UCB S.A. Company Details
Table 81. UCB S.A. Business Overview
Table 82. UCB S.A. Tumor Necrosis Factor (TNF) Inhibitor Drugs Product
Table 83. UCB S.A. Revenue in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2016-2021) & (US$ Million)
Table 84. UCB S.A. Recent Development
Table 85. Novartis International AG Company Details
Table 86. Novartis International AG Business Overview
Table 87. Novartis International AG Tumor Necrosis Factor (TNF) Inhibitor Drugs Product
Table 88. Novartis International AG Revenue in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2016-2021) & (US$ Million)
Table 89. Novartis International AG Recent Development
Table 90. Pfizer, Inc. Company Details
Table 91. Pfizer, Inc. Business Overview
Table 92. Pfizer, Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Product
Table 93. Pfizer, Inc. Revenue in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2016-2021) & (US$ Million)
Table 94. Pfizer, Inc. Recent Development
Table 95. Merck & co., Inc. Company Details
Table 96. Merck & co., Inc. Business Overview
Table 97. Merck & co., Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Product
Table 98. Merck & co., Inc. Revenue in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2016-2021) & (US$ Million)
Table 99. Merck & co., Inc. Recent Development
Table 100. Research Programs/Design for This Report
Table 101. Key Data Information from Secondary Sources
Table 102. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Type: 2020 VS 2027
Figure 2. Humira Features
Figure 3. Enbrel Features
Figure 4. Remicade Features
Figure 5. Simponi/Simponi Aria Features
Figure 6. Cimzia Features
Figure 7. Biosimilars Features
Figure 8. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Application: 2020 VS 2027
Figure 9. Rheumatoid Arthritis Case Studies
Figure 10. Psoriasis Case Studies
Figure 11. Psoriatic Arthritis Case Studies
Figure 12. Crohn’s Disease Case Studies
Figure 13. Ulcerative Colitis Case Studies
Figure 14. Ankylosing Spondylitis Case Studies
Figure 15. Juvenile Idiopathic Arthritis Case Studies
Figure 16. Hidradenitis Suppurativa Case Studies
Figure 17. Others Case Studies
Figure 18. Tumor Necrosis Factor (TNF) Inhibitor Drugs Report Years Considered
Figure 19. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 20. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 21. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Regions: 2020 VS 2027
Figure 22. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Regions (2022-2027)
Figure 23. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Players in 2020
Figure 24. Global Top Tumor Necrosis Factor (TNF) Inhibitor Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Tumor Necrosis Factor (TNF) Inhibitor Drugs as of 2020
Figure 25. The Top 10 and 5 Players Market Share by Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue in 2020
Figure 26. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share by Type (2016-2021)
Figure 27. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share by Type (2022-2027)
Figure 28. North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Type (2016-2027)
Figure 30. North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Application (2016-2027)
Figure 31. North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Country (2016-2027)
Figure 32. United States Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Canada Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Type (2016-2027)
Figure 36. Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Application (2016-2027)
Figure 37. Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Country (2016-2027)
Figure 38. Germany Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. France Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. U.K. Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Italy Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Russia Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Nordic Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Type (2016-2027)
Figure 46. Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Application (2016-2027)
Figure 47. Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Region (2016-2027)
Figure 48. China Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Japan Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. South Korea Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Southeast Asia Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. India Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Australia Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Type (2016-2027)
Figure 56. Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Application (2016-2027)
Figure 57. Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Country (2016-2027)
Figure 58. Mexico Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Brazil Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Middle East & Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. Middle East & Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Type (2016-2027)
Figure 62. Middle East & Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Application (2016-2027)
Figure 63. Middle East & Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Country (2016-2027)
Figure 64. Turkey Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 65. Saudi Arabia Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 66. UAE Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 67. AbbVie Inc. Revenue Growth Rate in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2016-2021)
Figure 68. Amgen Inc. Revenue Growth Rate in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2016-2021)
Figure 69. Johnson & Johnson Services, Inc. Revenue Growth Rate in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2016-2021)
Figure 70. UCB S.A. Revenue Growth Rate in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2016-2021)
Figure 71. Novartis International AG Revenue Growth Rate in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2016-2021)
Figure 72. Pfizer, Inc. Revenue Growth Rate in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2016-2021)
Figure 73. Merck & co., Inc. Revenue Growth Rate in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2016-2021)
Figure 74. Bottom-up and Top-down Approaches for This Report
Figure 75. Data Triangulation
Figure 76. Key Executives Interviewed

---